Biofrontera Inc.
BFRINasdaq
$1.09
↓ -1.8%Jul 17 close · end-of-day
Price
1Y↑ +30.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$12.7M
Enterprise Value
$6.4M
P/E
—
P/S
0.3
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
-73.2%
Dividend Yield
—
Revenue (TTM)
$43.2M
Net Income (TTM)
-$11.1M
Free Cash Flow (TTM)
-$9.3M
Gross Margin
—
Operating Margin
-25.7%
Net Margin
-25.7%
ROE
-182.6%
ROIC
—
Debt / Equity
—
Net Cash
$6.3M
Return 1Y
+28.1%
Company profile
Biofrontera Inc. engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device. The RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
- CEO
- Erica L. Monaco
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- Massachusetts
- Website
- biofrontera.us.com
Management & directors
- Leffler Eugene FrederickChief Financial Officer
- Luebbert HermannCEO & Chairman
Roles derived from SEC Form 4 filings.
Earnings
BFRI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.1M↑ +17.4%
Diluted EPS-$0.41↓ -12.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $18.8M | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.6M | -$25.2M | -$18.6M | -$22.7M | -$17.2M | -$11.3M |
| Net income | -$11.0M | -$37.7M | -$640,000.00 | -$20.1M | -$17.8M | -$10.5M |
| Diluted EPS | — | — | -$0.61 | -$13.02 | -$3.22 | -$1.04 |
| Operating cash flow | -$12.4M | -$26.7M | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
| Free cash flow | — | — | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -51.0% | -104.6% | -64.8% | -66.6% | -46.1% | -27.2% |
| Net margin | -58.3% | -156.5% | -2.2% | -59.1% | -47.6% | -25.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $9.0M | $12.6M | $8.6M | $9.0M | $7.0M | $17.1M | $10.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.1M | -$5.0M | -$1.7M | -$4.5M | -$5.1M | -$6.3M | $4.6M | -$4.3M |
| Net income | -$257,000.00 | -$5.7M | -$1.4M | -$4.2M | -$5.3M | -$6.6M | $5.6M | -$4.8M |
| Diluted EPS | -$0.05 | -$0.98 | $0.69 | -$0.47 | -$0.57 | -$0.62 | $0.62 | -$0.41 |
| Operating cash flow | -$4.7M | -$1.2M | -$1.0M | -$4.1M | -$3.0M | -$3.8M | -$2.4M | -$70,000.00 |
| Free cash flow | -$4.8M | -$1.2M | -$1.0M | -$4.1M | -$3.0M | -$3.8M | -$2.4M | -$75,000.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -64.7% | -55.0% | -13.6% | -52.9% | -56.2% | -89.8% | 26.6% | -42.8% |
| Net margin | -3.3% | -62.9% | -11.1% | -48.9% | -59.0% | -95.1% | 33.0% | -47.1% |
Company news
May 19, 2026
May 14, 2026
- 66d agoBiofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...finance.yahoo.com
- 67d agoBiofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimatesfinance.yahoo.com
- 67d agoBiofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Updatefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-05 | Luebbert Hermann· CEO & Chairman | Option exercise | 137,500 | — | — | filing |
| 2026-03-05 | Leffler Eugene Frederick· Chief Financial Officer | Option exercise | 87,500 | — | — | filing |
| 2025-09-10 | Luebbert Hermann· CEO & Chairman | Option exercise | 137,500 | — | — | filing |
| 2025-09-10 | Leffler Eugene Frederick· Chief Financial Officer | Option exercise | 87,500 | — | — | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.